Carbohydrate feeding dissociates the postprandial FGF19 response from circulating bile acid levels in humans

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages

  Morton, Gregory J ^a   Kaiyala, Karl J ^a   Foster Schubert, Karen E ^a,b   Cummings, David E ^a,b   Schwartz, Michael W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BILE ACIDS AND SALTS; CROSS-OVER STUDIES; DIETARY CARBOHYDRATES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 84893785854     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3129     Document Type: Article

References (22)

1. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8:235-253.
2. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factordependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003;17:1581-1591.
3. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009; 89:147-191.
4. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 2004;145:2594-25603.
5. Morton GJ, Matsen ME, Bracy DP, et al. FGF19 action in the brain induces insulin-independent glucose lowering. J Clin Invest. 2013; 123:4799-4808.
6. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331:1621-1624.
7. Gälman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology. 2005;129:1445-1453.
8. Lundasen T, Gälman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med. 2006;260:530-536.
9. Roberts RE, Glicksman C, Alaghband-Zadeh J, Sherwood RA, Akuji N, le Roux CW. The relationship between postprandial bile acid concentration, GLP-1,PYYand ghrelin. Clin Endocrinol (Oxf). 2011;74:67-72.
10. Witteman BJ, Jebbink MC, Hopman WP, Masclee AM, Lamers CB, Jansen JB. Gallbladder responses to modified sham feeding: effects of the composition of a meal. J Hepatol. 1993;19:465-469.
11. Foster-Schubert KE, Overduin J, Prudom CE, et al. Acyl and total ghrelin are suppressed strongly by ingested proteins, weakly by lipids, and biphasically by carbohydrates. J Clin Endocrinol Metab. 2008;93:1971-1979.
12. Harris JA, Benedict FG. A Biometric Study of Basal Metabolism in Man. Washington, DC: Carnegie Institution of Washington; 1919.
13. Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression. Hepatology. 2009;49:297-305.
14. Ryan KK, Kohli R, Gutierrez-Aguilar R, Gaitonde SG, Woods SC, Seeley RJ. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology. 2013;154:9-15.
15. WuAL, Coulter S, Liddle C, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One. 2011;6:e17868.
16. Wu AL, Kolumam G, Stawicki S, et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med. 2011;3:113ra126.
17. Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab. 2011;13:729-738.
18. Thorens B, Waeber G. Glucagon-like peptide-I and the control of insulin secretion in the normal state and inNIDDM.Diabetes. 1993; 42:1219-1225.
19. Shang Q, Guo GL, Honda A, Saumoy M, Salen G, Xu G. FGF15/19 protein levels in the portal blood do not reflect changes in the ileal FGF15/19 or hepatic CYP7A1 mRNA levels. J Lipid Res. 2013;54: 2606-2614.
20. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005;1: 361-370.
21. Gerhard GS, StyerAM,WoodGC, et al.Arole for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013;36:1859-1864.
22. Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153:3613-3619. Diseases Diseases Diseases Diseases Diseases Diseases